




How the Role of Medical Affairs Is Evolving in 2021



Keeping up with an ever-changing health care ecosystem starts with investing in the right talent and organizational structure to support your strategy. Medical leaders at life science companies across the industry—from small firms with nascent medical affairs groups to multi-BU conglomerates—are continuously iterating on their organizational model and creating new roles to better address emerging priorities. Below, we outline three key ways the medical affairs function is evolving.

 **LEARN MORE**

Want to learn more about our research? Check us out at advisory.com/medicalleader or email medicalleader@advisory.com



01 To elevate their impact across the product lifecycle, medical leaders are creating new roles that formalize connections with internal and external customers.

Most companies recognize the value of leveraging their medical teams for insight and feedback, but it's not always clear how to operationalize that goal. While organizational structures vary significantly by company, many firms are starting to formalize medical affairs' connections with colleagues and customers by creating new roles dedicated to bridging specific stakeholder groups.

Most of these roles are specifically designed to foster communication, collaboration, and coordination. Several report up through medical affairs, but some sit adjacent to medical and serve as liaisons to other functions like HEOR, market access, or key accounts. Below are several examples of roles designed to support specific organizational goals.


Roles designed to support coordinated evidence generation:

- **RWE Center of Excellence Lead** to prioritize and coordinate RWE projects across the portfolio
- **Head of Evidence and Value** to ensure customer-driven endpoints are included in upstream, clinical development decisions
- **Hybrid Medical and Market Access** role to support parallel development of medical and economic value narratives

Roles designed to elevate external stakeholder engagement:

- **Medical Account Managers** to work alongside medical science liaisons so they can more effectively engage IDNs and develop partnership opportunities
- **Health Technology Assessment Liaisons** to monitor HTA activity and facilitate proactive participation in reviews
- **Digital Medical Strategy Groups** to develop digital content and communication strategies for HCP and patient audiences

Today, the majority of these “bridge” roles support collaboration with downstream commercial functions, but there is untapped opportunity to work more closely upstream—particularly with R&D. Given their insight into how payers and providers make decisions, medical teams are uniquely suited to weigh in on evidence needs early in the product lifecycle, which can save their organizations time and money on downstream and post-launch studies.




02 Life science companies are continually adapting their organizational models to optimize RWE generation and use.

As new sources of real-world data emerge and become more usable, organizations are investing in additional capabilities to incorporate RWE as a key component of the value narrative. In particular, they are focused on optimizing existing data assets, coordinating projects across the enterprise, and evaluating new use cases for RWE. Often these priorities are reflected in changes—some subtle and others substantial—to existing models for evidence generation.

Some organizations, particularly large organizations with multiple business units, are developing an above-brand RWE Center of Excellence to centralize planning and operations. A centralized model can help prevent duplicative data purchases and reduce the risk of analyses producing different results. Other organizations are expanding the medical or HEOR function to include RWE management, depending on which kinds of customers or products are highest priority.

Regardless of the specific model, there are a few best practices applicable to every organization:

- Formalize processes for cross-functional alignment on RWE use.
- Streamline the acquisition and maintenance of real-world data sets.
- Develop predetermined metrics for RWE success (including, but not limited to, regulatory approvals or value-based contracts).
- Train field staff to communicate RWE effectively and anticipate sources of concern.
- Lead company-wide education initiatives to raise awareness of RWE studies and capabilities.




03 **As medical information becomes more available, tailored, and actionable through digital platforms, the role of the MSL must evolve—but how it evolves is up for debate.**

Given the proliferation of online physician networks, social media, and online journals, medical information has never been more widely available or as easily accessible. This begs a sobering question: If HCPs and other clinical customers can theoretically access the information they need on-demand online, what value does the medical science liaison (MSL) bring to the conversation? How must the role of the MSL evolve in this new information ecosystem?

On one hand, HCPs and other customers have access to a nearly infinite amount of information online. With the help of digital tools and artificial intelligence, that information is becoming increasingly curated and tailored to specific audiences. In theory, HCPs may not rely as heavily on MSLs to distill and share relevant clinical information, because that job will be accomplished quite well via digital technologies. On the other hand, with so much clinical information available online, HCPs may still lean on trusted MSLs to make sense of the overwhelming amount of information available, especially when newly released data challenges previously held assumptions about certain diseases, populations, or treatment options. For the foreseeable future, an MSL's ability to field customer questions, diagnose customers' evidence needs, and situate new data within the larger context of previously available evidence will remain vitally important. However, the ways that MSLs deliver those services and incorporate advanced digital technologies (like artificial intelligence) are likely to change.

As the medical/scientific information-sharing landscape continues to evolve, the role of the MSL must adapt alongside it. The information MSLs will need to share, the ways they will disseminate it, and the ways that customer insights get fed back into life sciences organizations will ultimately depend on how HCP information consumption also evolves.

 Want to learn more about our research? Check us out at advisory.com/medicallleader or email medicallleader@advisory.com

CREDITS

PROJECT DIRECTOR

Pamela Divack

PROGRAM LEADERSHIP

Brandi Greenberg

CONTRIBUTING EXPERTS

Solomon Banjo

Katie Schmalkuche

Daphney Gaston

DESIGNER

Kate Young

LEGAL CAVEAT

Advisory Board has made efforts to verify the accuracy of the information it provides to members. This report relies on data obtained from many sources, however, and Advisory Board cannot guarantee the accuracy of the information provided or any analysis based thereon. In addition, Advisory Board is not in the business of giving legal, medical, accounting, or other professional advice, and its reports should not be construed as professional advice. In particular, members should not rely on any legal commentary in this report as a basis for action, or assume that any tactics described herein would be permitted by applicable law or appropriate for a given member's situation. Members are advised to consult with appropriate professionals concerning legal, medical, tax, or accounting issues, before implementing any of these tactics. Neither Advisory Board nor its officers, directors, trustees, employees, and agents shall be liable for any claims, liabilities, or expenses relating to (a) any errors or omissions in this report, whether caused by Advisory Board or any of its employees or agents, or sources or other third parties, (b) any recommendation or graded ranking by Advisory Board, or (c) failure of member and its employees and agents to abide by the terms set forth herein.

Advisory Board and the "A" logo are registered trademarks of The Advisory Board Company in the United States and other countries. Members are not permitted to use these trademarks, or any other trademark, product name, service name, trade name, and logo of Advisory Board without prior written consent of Advisory Board. All other trademarks, product names, service names, trade names, and logos used within these pages are the property of their respective holders. Use of other company trademarks, product names, service names, trade names, and logos or images of the same does not necessarily constitute (a) an endorsement by such company of Advisory Board and its products and services, or (b) an endorsement of the company or its products or services by Advisory Board. Advisory Board is not affiliated with any such company.

IMPORTANT: Please read the following.

Advisory Board has prepared this report for the exclusive use of its members. Each member acknowledges and agrees that this report and the information contained herein (collectively, the "Report") are confidential and proprietary to Advisory Board. By accepting delivery of this Report, each member agrees to abide by the terms as stated herein, including the following:

1. Advisory Board owns all right, title, and interest in and to this Report. Except as stated herein, no right, license, permission, or interest of any kind in this Report is intended to be given, transferred to, or acquired by a member. Each member is authorized to use this Report only to the extent expressly authorized herein.
2. Each member shall not sell, license, republish, or post online or otherwise this Report, in part or in whole. Each member shall not disseminate or permit the use of, and shall take reasonable precautions to prevent such dissemination or use of, this Report by (a) any of its employees and agents (except as stated below), or (b) any third party.
3. Each member may make this Report available solely to those of its employees and agents who (a) are registered for the workshop or membership program of which this Report is a part, (b) require access to this Report in order to learn from the information described herein, and (c) agree not to disclose this Report to other employees or agents or any third party. Each member shall use, and shall ensure that its employees and agents use, this Report for its internal use only. Each member may make a limited number of copies, solely as adequate for use by its employees and agents in accordance with the terms herein.
4. Each member shall not remove from this Report any confidential markings, copyright notices, and/or other similar indicia herein.
5. Each member is responsible for any breach of its obligations as stated herein by any of its employees or agents.
6. If a member is unwilling to abide by any of the foregoing obligations, then such member shall promptly return this Report and all copies thereof to Advisory Board.



655 New York Avenue NW, Washington DC 20001
202-266-5600 | [advisory.com](https://www.advisory.com)